top of page

Solving autoimmunity at the source.

The pinnacle of autoimmune care.

We are Rarefied Biosciences — advancing first-in-class, oral therapies that will transform the treatment of autoimmune diseases. Our lead program, RB201, has successfully completed Phase 1 human trials, unlocking the potential for a safer and more effective way forward for tens of millions of patients worldwide.

Rarefied_Tcell-Bcell.png
Rarefied_Mountains.png

A New Approach to Autoimmunity.

Every autoimmune drug today fights the avalance at the bottom of the mountain. We're stopping it at the top.

Rarefied Bio “re-tunes” immune cells without compromising the body’s natural defenses.

How it works
Manish_Butte.jpg

Manish Butte, MD PhD

Our founder Dr. Butte has 20 years of experience as a practicing clinical immunologist and physician-scientist at world-leading academic institutions. He leads a large clinical and research enterprise, 200+ publications, NIH-funded for decades, founder of two prior startups.

Our Team

World-class scientist, doctor, and leader

UCLA has no relationship with and does not endorse Rarefied Bio.

Butte-Schools.jpg
RB_Logo.png

Stopping the avalanche of autoimmunity at the top of the mountain

Rarefied_Mountains.png

Our Pipeline

Our lead program, RB201, is the first and only oral medicine of its kind in clinical development for autoimmunity and has successfully completed Phase 1 human trials. RB202, our second program, further advances autoimmune treatments.

bottom of page